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Measuring eUipticities of (+)-colchicine and (+)-deacetamidocolchicine in th presence of tubulin afforded net positive 
CD bands with maxima t 340 nm resulting from reduction of the negative iliptiCities upon binding of (-) enantiomers 
to the protein. Results of optical studies together with earlier NMR conforrnational nalysis of these molecules substanti- 
ate the hypothesis that colchicinoids bind to tubuiin with the phenyl-tropolone moiety in the 'aS' configuration. Natural 
colchicine which binds to tubulin, therefore, should be referred to as (-)-(aS,7S)-colchicine. 
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1. INTRODUCTION 
Colchicine, the major  a lkalo id f rom Colchicum 
autumnale, has ant imitot ic propert ies,  and is used 
medic inal ly  for the treatment o f  gout and Fami l ia l  
Medi ter ranean Fever [2-4]. Colchicine inhibits 
microtubule  assembly both in vitro and in vivo by 
b inding with high aff inity to tubul in [5], a ma jor  
prote in  subunit  o f  microtubules.  A l though the 
results o f  ant i tumor activity and tubul in binding 
studies o f  a large number  of  cholchicinoids had in- 
d icated the importance o f  the spatial  arrangement 
o f  the four  methoxy groups in the drug-prote in in- 
teract ion,  the mechanism of  interact ion is still not 
clearly understood.  A recent report  [6] which sug- 
gested that an aS conf igurat ion o f  the phenyl-  
t ropo lone  moiety was essential for the interact ion 
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Note: The italic letter a before the corresponding R and S 
denotes an axial chirality originating from a biaryl system as 
suggested by Calm et al. [1] 
with the protein would therefore deserve special at- 
tent ion.  Support  for this hypothesis has now been 
obta ined f rom circular d ichroism (CD) 
measurements  o f natura l  (-)-(7S)-colchicine, un- 
natura l  (+)-(7R)-colchic ine,  (+) -co lch ic ine and 
(=t=)-deacetamidocolchicine with and without addi-  
t ion o f  bovine bra in  tubul in.  
2. MATERIALS  AND METHODS 
Natural (-)-(7S)-colchicine was purchased from Fluka 
(Ronkonkoma, NY). Unnatural (+)-(7R)-colchicine was 
prepared as in [7]. Deacetamidocolchicine was made by 
catalytic reduction (Pd/C in ethyl acetate) of deacetamido-5, 
6-dehydrocolchicine, prepared according to [8]. Deacetami- 
docolchicine, thus prepared, showed chemical and physical pro- 
perties identical with material obtained by total synthesis [9]. 
All other chemicals were obtained commercially. Tubuiin was 
purified from bovine brain using the published procedure [10] 
and stored in liquid nitrogen at a protein concentration f 54 
mg/ml of I M sodium glutamate solution at pH 6.6 before use. 
Samples of tubulin for the CD experiments were prepared by 
rapidly thawing the stored material, followed by centrifugation, 
if needed to remove small amounts of denatured protein, and 
then diluting to a final protein concentration f approx. 2-2.5 
mg/ml of buffer (1 M sodium glutamate, pH 6.6, 0.1 M a-D- 
,glucose 1-phosphate, 1 mM MgCI2 and 0.1 mM guanosine 
3'-diphosphate). Concentrations of tubulin were determined 
according to Lowry et al. [11] or the method in [12] (The pro- 
tein assay kits, purchased from Bio-Rad (Rockville Centre, 
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NY), were used for measuring total protein concentration. The 
method is based on the Bradford ye-binding procedure [12].). 
Colchicine stock solutions were prepared by first dissolving col- 
chicine in 0.5 ml methanol, then adding 0.5 ml buffer to obtain 
a final drug concentration of 2.2 raM. CD spectra were 
measured on a Jasco model JS00A spectropolarimeter quipped 
with a data processing system for signal averaging. All spectra 
were taken at 24°C, using a 1 cm cell and a full-scale sensitivity 
of 40 x 10 -3 degree. Ten scans were accumulated and averaged 
on all solutions. Aliquots of the drug stock solution were in- 
troduced into 3-ml samples of either buffer or tubulin solution 
in the CD cell. The CD spectra were measured about 15-20 min 
after sample mixing. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the CD spectra in buffer solutions 
of  natural (7S)-colchicine, unnatural (7R)- 
colchicine and each with tubulin (2 :1 ) in  the 
wavelength range between 250 and 400 nm. The 
CD spectrum of natural (7S)-colchicine is 
characterized by a major negative band with a 
maximum at about 340 nm and a minor negative 
band at about 265 nm (curve A), while that of un- 
natural (7R)-colchicine displays a mirror-image 
CD spectrum with positive CD bands (curve C). 
The optical characteristics exhibited by (7S)- 
colchicine and (7R)-colchicine appear to originate 
from the phenyl-tropolonic system (A and C 
rings), rather than the C-7 chiral center of ring B 
(scheme 1). Support for this conclusion is based on 
the following: In addition to atomic chirality at 
C-7, colchicine also possess axial chirality 
originating from the phenyl-tropolonic moiety. A 
recent NMR study [6] revealed that colchicinoids 
can undergo aS-aR phenyl-tropolonic someriza- 
tion [6,14] and the position of the aS-aR equilibria 
appears  to be dependent upon the nature of the 
substituents at C-7 of ring B [6]. NMR spectral 
analysis indicated that both (C)-7 acetamido 
groups of natural (7S)- and unnatural (7R)- 
colchicine prefer the equatorial over the axial 
orientation. This conformational preference of the 
acetamido group causes natural (7S)-colchicine to 
adopt the aS configuration, whereas unnatural 
(7R)-colchicine adopts the aR configuration. Thus, 
the large negative rotation observed for natural 
(7S)-colchicine is attributed to the (aS, TS) con- 
former, whereas the positive rotation of unnatural 
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Fig. 1. CD spectra of colchicine (40/~M) in the presence and absence oftubulin (20/~M) over the wavelength range 250-400 nm. Curves: 
(A) natural (-)-colchicine; (13) natural (-)-colchicine and tubulin (2:1); ((2) unnatural (+)-colchicine; (D) unnatural (+)-colchicine and 
tubulin (2:1); (E) tubulin only. 
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(+)-deacetamidocolchicine (having only axial 
chirality) exhibited a net positive CD spectrum 
similar to that of unnatural (7R)-colchicine (having 
atomic and axial chiralities) in the presence of 
tubulin (as will be discussed later), the optical rota- 
tion exhibited by these colchicinoids therefore is 
attributed to the axial chirality originating from 
the phenyl-tropolonic moiety rather than the C-7 
chiral center. This conclusion is further supported 
by optical measurements of a CDC13 solution of 
(7S)-l-acetyl-l-demethylcolchicine i  which a 
reduction of negative rotation values ([t~]D) from 
--185 at 22°C to -76  at 50°C [13] was accom- 
panied, respectively, by a change in molar ratio of 
aS to aR conformers from about 1:0.4 to 1:0.8 as 
measured by NMR. 
The CD spectrum of tubulin is characterized by 
a large negative band at about 272 nm and a small 
positive band at 295 nm (fig.l, curve E), 
presumably contributed by aromatic residues and 
disulfides of the protein. No CD absorption was 
observed above 310 nm for tubulin. 
Addition of natural (-)-(7S)-colchicine to 
tubulin resulted in a notable reduction of the ellip- 
ticity above 310 nm (fig.l, curve B) when com- 
pared to an equal concentration of protein-free 
colchicine (curve A), whereas no discernible reduc- 
tion was seen when unnatural (+)-(7R)-colchicine 
was added to tubulin (fig.l, curves C,D). These 
observations indicated that tubulin interacts with 
the former but not the latter enantiomer, and only 
with colchicine in the aS-biaryl configuration. The 
requirement for the aS-biaryl configuration of col- 
chicine for binding to tubulin was demonstrated by
a CD study of (+)-colchicine having equimolar 
amounts of (75')- and (7R)-colchicine, and (+)- 
deacetamidocolchicine which possesses only axial 
chirality. Fig.2 shows the difference llipticity at 
340 nm when measured in the presence and 
absence of a fixed concentration of tubulin (20 
/zM) for (-)-(7S)-colchicine, (+)-(7R)-colchicine, 
(+)-colchicine and deacetamidocolchicine with 
drug enantiomer/tubulin ratios ranging from 0 to 
3 mol/mol. The difference llipticity (A#, drug plus 
tubulin - drug only) at 340 nm when natural (-)- 
(7S)-colchicine is added to tubulin showed an in- 
creasing positive rotational strength which finally 
levelled off at molar ratios above - 1.25-1.5 
(fig.2A), which is in reasonably good agreement 
with the 1:1 stoichiometry as reported from other 
binding studies [15]. Using the CD titration data 
together with a Scatchard plot, the association 
constant for the drug-tubulin (1:1) binding was 
roughly estimated at 0.1/zM-z, which is within the 
range of reported values (0.05-5/zM- 1) [16,17]. No 
notable difference llipticity was observed for un- 
natural (+)-(7R)-colchicine (fig.2B), confirming 
its lack of binding to tubulin. The titration of 
tubulin with (+)-colchicine (fig.2C), which show- 
ed a zero rotation value in the absence of tubulin 
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Fig.2. Difference Uipticities (AO) at 340 nm (drug plus protein 
- drug only) measured in the presence and absence of tubulin 
(20/~M) for natural (-)-colchicine (A), unnatural (+)-colchicine 
(B), racemic (+)-colchicine (C) and deacetarnidocolchicine (D) 
at drug enantiomer/tubulin ratios in the range 0-3 tool/tool 
(enantiomer concentration is 0.5 of racemic mixture). 
(not shown), afforded ifference llipticity at 340 
nm with positive rotation values which increased 
and slowly levelled off. Such changes of CD spec- 
tra are expected since the negative CD band at 340 
nm contributed by (-)-(7S)-colchicine is reduced 
upon binding to tubulin and leaves the unbound 
colchicine in solution with excess (+)-(7R)-col- 
chicine, resulting in a net positive CD band. This 
net positive CD band remains unchanged even 
after 24 h, since unbound (7R)-colchicine r mains 
predominantly in an aR-biaryl conformation 
regardless of binding of (7s)-colchicine totubulin. 
However, this situation is significantly different 
for deacetamidocolchicine. Deacetamidocolchicine 
which has equal concentrations of aS and aR con- 
formers also exhibits zero ellipticity at 340 nm in 
the absence of tubulin. Titration of tubulin with 
deacetamidocolchicine gave CD spectra similar to 
those observed with (_)-colchicine (fig.2D), con- 
firming that it is indeed the aS conformer of deace- 
tamidocolchicine which binds to tubulin, leaving 
the aR conformer unbound, and thus resulting in 
a positive CD band. Unlike ( + )-colchicine, the net 
positive CD band of the unbound eacetamidocol- 
chicine observed in the presence of tubulin was 
gradually reduced and finally disappeared after 
about 24 h. This agreed with our expectations since 
reestablishment of an aS-aR equilibrium from a 
predominantly aR conformer to equal concentra- 
tions of aS and aR conformers (which give no CD 
band), takes place at the rate of the biaryl iso- 
merization, which has been reported to be in the 
range of 1 x 10 -4 s -~ for a number of colchici- 
noids [6,14]. Although reduction of optical rota- 
tion of natural (-)-colchicine on binding to 
tubulin was previously reported [17], the present 
study with (+)-colchicine and (+)-deacetamido- 
colchicine provides the first demonstration that it 
is the ( - )-(aS) enantiomer which binds to the pro- 
tein, leaving the (+)-(aR) enantiomer unbound. 
4. CONCLUSIONS 
The present results provide evidence supporting 
the hypothesis that, in addition to the structural 
and spatial requirements (i.e. the positioning of the 
four methoxy groups in colchicinoids), it is the 
conformation ofthe phenyl-tropolone system in an 
aS configuration which is required for binding to 
tubulin. The CD data also demonstrate hat the 
high negative rotations measured for colchicinoids 
stem from the aS configuration of the biaryl 
system rather than the contribution by the C(7) 
chiral center. Natural colchicine which binds to 
tubulin, therefore, should be referred to as (-)- 
(aS, 7S)-colchicine. 
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